Sign in
Back
143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab
Journal article   Peer reviewed

143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab

William J Sandborn, Severine Vermeire, Geert R D'Haens, Jean-Frederic Colombel, Richard N Fedorak, Martina E Spehlmann, Douglas C Wolf, Maria T Abreu, Krassimir Mitchev, Corinne Jamoul, …
Gastroenterology (New York, N.Y. 1943), Vol.136(5), pp.A-27-A-27
2009-05
DOI: https://doi.org/10.1016/S0016-5085(09)60126-8

Metrics

8 Record Views

Details